氯胺酮与致幻剂快速抗抑郁反应汇聚的神经免疫信号
该研究整合健康志愿者脑脊液蛋白质组与难治性抑郁症患者来源的诱导多能干细胞转录组,并在接受单次静脉氯胺酮或安慰剂的患者中开展转录组、脑磁图与血浆细胞因子多模态评估;发现IL-15与MCP-1为保守免疫调控枢纽,IL-7/IL-15轴相关细胞因子比值可预测抗抑郁应答与非应答。
要点
- 氯胺酮与血清素能致幻剂共享IL-15、MCP-1等神经免疫信号枢纽。
- 基线IL-15降低与B细胞信号升高见于氯胺酮应答者,治疗后逆转。
- IL-7与γ功率关联在难治性抑郁症中显著,氯胺酮后关系反转。
核心结论
- 氯胺酮与血清素能致幻剂虽受体靶点不同,但汇聚于共享的神经免疫信号通路。
- IL-15与MCP-1为跨脑脊液和iPSC神经元保守免疫通路的关键调控枢纽。
- IL-7/IL-15轴相关细胞因子比值可预测氯胺酮抗抑郁应答与非应答。
研究设计与样本
- 整合健康志愿者静脉氯胺酮后脑脊液蛋白质组与难治性抑郁症及健康志愿者来源iPSC转录组。
- iPSC分别经氯胺酮、2R,6R-羟基去甲氯胺酮、LSD或赛洛西宾处理。
- 对接受单次静脉氯胺酮0.5 mg/kg或安慰剂的患者开展转录组、脑磁图与血浆细胞因子多模态评估。
- 转录组样本为难治性抑郁症16例与健康志愿者11例;脑磁图为30例与25例;血浆细胞因子为39例与25例。
主要发现
- 脑脊液与iPSC神经元中识别出保守免疫通路,IL-15与MCP-1为关键调控枢纽。
- 全血转录组中,氯胺酮应答者基线IL-15降低、B细胞信号通路升高,治疗后逆转。
- 血浆IL-7水平与基线脑磁图γ功率相关,在所有参与者中达全脑显著性(主效应pFDR < 0.05)。
- 该关联在难治性抑郁症皮层下区域最显著(诊断×IL-7 pFDR < 10-14)。
- 氯胺酮后难治性抑郁症中IL-7-γ关系反转,伴随默认模式网络区域γ功率广泛降低(会话×IL-7 pclc < 0.05)。
关键数值与推荐
- 混合效应模型中,IL-4/IFN-γ比值预测抗抑郁应答(pFDR < 0.041)。
- MCP-1/IL-7比值预测非应答(pFDR < 0.009)。
- 提示IL-7/IL-15轴内再平衡可能参与疗效。
临床怎么用
- IL-7/IL-15轴相关细胞因子比值或可作为氯胺酮抗抑郁应答的候选预测标志物。
- 基线IL-15与B细胞信号通路变化可能辅助识别氯胺酮应答者。
- IL-7与γ功率关联及治疗后反转提示神经免疫-脑电耦合可用于疗效监测探索。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Despite distinct receptor targets, both ketamine and serotonergic psychedelics produce a rapid clinical response and share biological signatures that suggest convergence on common downstream molecular mediators. To identify shared biomarkers of rapid antidepressant response, this study integrated CSF proteomics from healthy volunteers (HVs) who received intravenous ketamine with transcriptomic analyses from induced pluripotent stem cells (iPSCs) derived from participants with treatment-resistant depression (TRD) and HVs; iPSCs were treated with ketamine, its metabolite (2 R,6 R)-hydroxynorketamine, lysergic acid diethylamide (LSD), or psilocybin. Multimodal clinical characterization (transcriptomics (n = 16 TRD; 11 HV), magnetoencephalography (MEG) (n = 30 TRD; 25 HV), and plasma cytokines (n = 39 TRD; 25 HV) were also performed on TRD and HV participants who received a single dose of intravenous ketamine (0.5 mg/kg) or placebo. Conserved immune pathways were identified across CSF and iPSC neurons with interleukin-15 (IL)-15 and monocyte chemoattractant protein-1 (MCP-1) emerging as key regulatory hubs. Transcriptomically, in whole blood, ketamine responders exhibited decreased IL-15 and elevated B-cell signaling pathways at baseline that were reversed post-treatment. At the protein level, plasma IL-7 levels (primary B-cell driver) correlated with baseline MEG gamma power, reaching brain-wide significance across all participants (main effect pFDR < 0.05). The association was most pronounced in the TRD participants across subcortical regions (diagnosis x IL-7 pFDR < 10-14). Post-ketamine, the TRD IL-7-gamma relationship inverted, paralleling widespread gamma power reductions throughout default-mode network regions (session x IL-7 pclc < 0.05). In mixed-effects models, cytokine ratios linked to IL-7/IL-15 signaling predicted antidepressant response (IL-4/interferon gamma (IFN-γ) pFDR < 0.041) and non-response (MCP-1/IL-7 pFDR < 0.009), suggesting that rebalancing within the IL-7/IL-15 axis may contribute to therapeutic efficacy. Clinicaltrials.gov identifier: NCT00088699; NCT02484456.
引用
- Jones GH, Gilbert JR, Johnston JN, et al. Convergent neuroimmune signaling underlying rapid antidepressant response to ketamine and psychedelics. Mol Psychiatry. 2026. PMID: 42521762. doi:10.1038/s41380-026-03777-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。